As expected, antibody blockade of PD-L1/PD-1 interactions, or absence of PD-1 expression in T cells led augmented tumor rejection, suggesting that PD-L1 represented a molecular shield protecting cancer cells from T-cell cytotoxicity [34,35,36]. Here, PDCD1 is linked to cancer.